1-4 of 4
Shili Lin
Close
Sort by
Journal Articles

Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Shangbin Yang, PhD, Senthil Sukumar, MD, Alcinda Flowers, MD, Haiwa Wu, Krista Carter, Shili Lin, Chenggon Han, Spero Cataland
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-142117
Published: 2020
Journal Articles

Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.

Spero Cataland, Shangbin Yang, April Horne, Shili Lin, James George, MD, Haifeng Wu, MD
Journal: Blood
Blood (2008) 112 (11): 2299.
https://doi.org/10.1182/blood.V112.11.2299.2299
Published: 2008
Journal Articles

ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.

Spero R. Cataland, MD, Ming Jin, PhD, Shili Lin, PhD, Melanie Kennedy, MD, Eric H. Kraut, MD, James N. George, MD, Haifeng M. Wu, MD
Journal: Blood
Blood (2007) 110 (11): 3204.
https://doi.org/10.1182/blood.V110.11.3204.3204
Published: 2007
Journal Articles

Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.

Haifeng M. Wu, MD, T. Charles Casper, Spero R. Cataland, M.D., Shili Lin, Ph.D., Melanie Kennedy, M.D., Ming Jin, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 4018.
https://doi.org/10.1182/blood.V110.11.4018.4018
Published: 2007